anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To identify clinical and demographic characteristics associated with prolapse recurrence by 12 months after native tissue transvaginal repair.
METHODS: This was a planned secondary analysis of a randomized trial including postmenopausal participants with stage 2 or greater apical or anterior vaginal prolapse scheduled for surgical repair at three U.S. sites. Participants underwent vaginal hysterectomy (if uterus was present) and standardized uterosacral or sacrospinous ligament suspension at the surgeon's discretion. The intervention was perioperative (5 weeks or more preoperatively and 12 months postoperatively) vaginal estrogen compared with placebo cream. The primary outcome was time to failure by 12 months after surgery, defined by objective prolapse of the anterior or posterior walls beyond the hymen or the apex descending more than one-third of the vaginal length, symptomatic vaginal bulge, or retreatment. For this analysis, participants were grouped according to failure compared with success, and multiple factors were compared, including age, time since menopause, race and ethnicity, parity, body mass index (BMI), baseline genital hiatus measurement, prolapse stage and point of maximal prolapse, surgery type (uterosacral or sacrospinous ligament suspension), and concomitant procedures. Factors were assessed for association with the hazard of surgical failure using Cox proportional hazards models, adjusted for site and treatment group. Factors with P <.50 from this analysis were considered for inclusion in the final multivariable model; site and treatment group were kept in this model.
RESULTS: One hundred eighty-six participants underwent surgery; 183 provided complete data. There were 30 failures (16.4%) and 153 successes (83.4%) at 12 months. On bivariate analysis, failure was associated with decreasing age, shorter duration since menopause, Latina ethnicity, and greater baseline genital hiatus. In the final multivariable model, which included age, BMI, and point of maximal prolapse, only age remained significantly associated with surgical failure (adjusted hazard ratio [per year] 0.92, 95% CI, 0.86-0.98, P =.016).
CONCLUSION: Among postmenopausal women, younger age was associated with increased frequency of prolapse recurrence by 12 months after native tissue repair.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT02431897.
Diagnosed with the obesity according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Diagnosed with a neurological disease or another clinical diagnosis that may affect the cognitive state, musculoskeletal and neurological disease, symptomatic heart disease, lung disease, diabetes, hypertension and malignant disease, which may affect the performance of exercise and using the drug that affects appetite and weight are the exclusion criteria.
Medicaments contg. a cpd. selected from the esters, amides and ester amides of D-, L- and DL-tyrosine and -phenylalanine, D-, L- and DL-phenylalanine, and salts in which the cation or anion derived from such a cpd. (the amides being linked via the N-atom of the amino-acid) increase the level of tyrosine in the blood, body fluids and tissues, with the consequence that levels of metabolites such as dopa, dopamine, (nor)-adrenaline and thyroxine are also increased. They are therefore useful in the treatment of e.g. nutritional disorders, Parkinson's disease, traumatic shock states and thyroid disorders. The medicaments are more effective in raising tyrosine levels than is tyrosine itself. Pref. medicaments contain cpds. of the formula: (where R1 is H or OH: R2 is H or acetyl, and R3 is H or ethyl, provided that R1 is not OH when both R2 and R3 are H).
Borderline elevations of one or more liver-associated enzymes may occur in up to 15% of patients taking NSAIDs, and notable elevations of ALT or AST (approximately 3 or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure (some with fatal outcome) have been reported with NSAIDs, including celecoxib [see Adverse Reactions (6.1)]. In controlled clinical trials of celecoxib, the incidence of borderline elevations (greater than or equal to 1.2 times and less than 3 times the upper limit of normal) of liver associated enzymes was 6% for celecoxib and 5% for placebo, and approximately 0.2% of patients taking celecoxib and 0.3% of patients taking placebo had notable elevations of ALT and AST.

A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be monitored carefully for evidence of the development of a more severe hepatic reaction while on therapy with celecoxib. If clinical signs and symptoms  
consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), celecoxib should be discontinued.
PURPOSE:To provide an agent for suppressing the absorption of nutrient, by using a water-absorbing substance composed of a water-soluble resin derived from starch and cellulose or composed of said water-soluble resin and an insolubilized CMC salt, expandable by the absorption of the water-soluble food in the digestive tracts, and giving the sense of satiety by taking only a small amount of the agent. CONSTITUTION:The objective agent for suppressing the absorption of nutrient is composed of a water-soluble resin derived from starch and cellulose or of said water-soluble resin and an insolubilized CMC salt. A concrete example of the water-absorbing substance is ''Sanwet I.M.1000'' (product of Sanyo Chemical Industry Co.). The water-soluble substance is dilated by absorbing the food which is made water-soluble by the gastric or intestinal juice, and the dilated lump presses the gastric wall to give the sense of satiety and prevent the obesity. It is effective at low rate of application compared with conventional agent. Since the dilated lump has moderate elasticity and softness, it can be applied safely without causing the blockage of the digestive tracts.
OBJECTIVE: To evaluate adherence and adherence consistency to the handheld ECG device-based screening protocol and their association with adverse cerebral and cardiovascular outcomes in two systematic atrial fibrillation (AF) screening programmes.
METHODS: In 2012 (Systematic ECG Screening for Atrial Fibrillation Among 75-Year Old Subjects in the Region of Stockholm and Halland, Sweden (STROKESTOP) study) and 2016 (Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide (STROKESTOP II) study), half of all 75- and 76-year-old inhabitants of up to two Swedish regions were invited to participate in a systematic AF screening programme. Participants were instructed to perform 30-second measurements twice daily in STROKESTOP and four times daily in STROKESTOP II for 2 weeks. Adherence was defined as the number of measurements performed divided by the number of measurements asked, whereas adherence consistency was defined as the number of days with complete registrations.
RESULTS: In total, 6436 participants (55.7% female) from STROKESTOP and 3712 (59.8% female) from STROKESTOP II were included. Median adherence and adherence consistency were 100 (92-100)% and 12 (11-13) days in STROKESTOP and 90 (75-98)% and 8 (3-11) days in STROKESTOP II. Female sex and lower education were factors associated with both optimal adherence and adherence consistency in both studies. In STROKESTOP, low adherence and adherence consistency were associated with higher risk of adverse cerebral and cardiovascular outcomes (HR for composite primary endpoint 1.30 (1.11 to 1.51), p=0.001), including stroke (HR 1.68 (1.22 to 2.32), p=0.001) and dementia (1.67 (1.27 to 2.19), p<0.001).
CONCLUSIONS: Adherence to twice daily handheld ECG measurements in STROKESTOP was higher than to four times daily measurements in STROKESTOP II. Female sex and lower educational attainment were associated with ≥100% adherence and adherence consistency. Low adherence and adherence consistency were associated with a higher risk of adverse outcomes.
Nebivolol 5 mg tablets. One nebivolo tablet daily. One placebo tablet daily.
Aims: Exercise interventions positively affect numerous cardiometabolic risk factors. To better evaluate the health effects of exercise training, it may be more appropriate to evaluate risk factors together. The Metabolic Syndrome Severity Score (MetSSS) is a composite score representing cardiometabolic risk. Purpose: To evaluate the relationships between physical activity, neuromuscular fitness, exercise capacity, and the MetSSS in a heterogenous sample of people with complex chronic disease. Material and Methods: Fifty-three people with kidney or liver disease and at least one feature of the metabolic syndrome (MetS) were included. Pearson correlations were conducted between physical activity, neuromuscular fitness, exercise capacity, and the MetSSS. Linear regressions were performed for multi-level categorical variables. Independent variables with an association with MetSSS (P ≤ 0.2) were included in a multiple regression analysis. Results: The 6-minute walk test (6MWT) distance was inversely and independently associated with MetSSS [standardized beta coefficient (β) = -0.31, P = 0.04]. No relationship was found between MetSSS and physical activity or neuromuscular fitness. Mean 6MWT in the highest tertile was 550 m (range: 505-620 m) and 346 m (range: 233-408 m) in the lowest. The analysis showed a medium-large between-group effect for the difference in MetSSS for the lowest and highest tertile of 6MWT [Eta squared (η2) = 0.16, P = 0.01]. Conclusions: Exercise capacity was inversely and independently associated with MetSSS in people with complex chronic disease. Clinical trials with exercise interventions are needed to further investigate if improvements in exercise capacity result in clinically significant changes in the MetSSS.
Embodiments of the present disclosure provide a system and method for using facial recognition and mimicry workflows to train cognitive and emotional empathy. The system and methods comprise the use of physiological measurements (e.g., EEG, etc.) in combinations with facial recognition to detect user affect and modify one or more cognitive screening instruments to further promote a user affect. One or more specific emotions associated with one or more specific negative cognitive bias are targeted to influence affect. One or more specific psychopathology may be treated using an emotional recognition training component within a computerized cognitive-bias modification regimen. The regimen may comprise the identification, targeting, and modification of emotions and may utilize one or more facial inputs, cognitive tasks, facial recognition and facial mimicry protocols to adaptively modify one or more attributes of one or more computerized stimuli or interactions within a computerized platform or platform-product.
The present invention relates to the chloera vaccine prepared from transgenic carrot and its process. The PCR method is used to clon CTB gene into plant expression vector to botain the plant expression vector pBirc38 of CTB. The vector is transformed into Agrobacterium tumefaciens, which is then used to transform into hypocotyl of carrot. After B5 and MS culutures, the carrot plant with kanamycin resistnace is obtained. The transformed hypocotyl cells for B5 culture or the calli for MS culture can be directly differentiated to grow transgenic plant. The CTB protein can be efficiently expressed in carrot and the CTB expressed by carrot root has bioactivity.
PCT No. PCT/GB95/00856 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed Apr. 13, 1995 PCT Pub. No. WO95/28642 PCT Pub. Date Oct. 26, 1995The invention relates to a diagnostic test for the detection and identification of Mycobacterium species in biological specimens of human and animal origin. The test is based on the immunological detection of one or more antigens originating from Mycobacterium. To enable the detection of an antibody-antigen reaction, the antibodies specific for these antigens can be labelled with an enzyme or fluorescent dye or attached to latex particles or any other suitable label. The diagnostic test may be in a form of ELISA and may or may not require concentration of the Mycobacterium antigens prior to the actual test. The invention comprises: the selection and procurement of a suitable mycobacterial species and strain, the isolation and purification of the antigens, preparation of the necessary conjugates for the immunization of the experimental animals using various carrier molecules, the development of an assay for monitoring the antibody production, characterisation of the antibodies specific for the Mycobacterium antigen/antigens and the development of a diagnostic assay/kit.
A polyphenol diglucoside compound, a preparing method thereof and applications of the compound are disclosed. The structure of the polyphenol diglucoside compound is shown as a formula (I). The preparing method includes putting smashed whole plant of chloranthus spicatus (Thunb.) makino into an organic solvent, digesting, separating to obtain leach liquor, extracting the leach liquor, concentrating extract liquid to obtain an extract, and subjecting the extract to chromatographic separation for purification to obtain the polyphenol diglucoside compound. The organic solvent is one or a mixture of a plurality of solvents selected from methanol, ethanol, n-butanol and acetone. The polyphenol diglucoside compound having a novel structure is obtained by extracting the whole plant of the chloranthus spicatus (Thunb.) makino and separating. The compound is good in tyrosinase inhibiting activity, can be used for preparing tyrosinase inhibiting medicines, whitening cosmetics or whitening healthcare foods, and has a good development prospect.
BACKGROUND: Endometrial cancer is a kind of gynaecological cancer. S100A2 is a newfound biomarker to diagnose endometrial cancer. This study was to investigate the role of S100A2 on regulating migration and invasion of endometrial cancer.
METHODS: The mRNA and protein levels of S100A2 were obtained by quantitative real-time polymerase chain reaction, immunohistochemistry and western blot methods. Cell viability was measured by the Cell Counting Kit-8 assay. Cell migration and invasion were quantified using transwell assays. Western blot assay was conducted to quantify protein expressions of epithelial to mesenchymal transition-related proteins (N-cadherin and E-cadherin). Furthermore, in vivo tumour formation experiments were performed to evaluate the role of S100A2 on tumour xenografts.
RESULTS: S100A2 was significantly up-regulated in endometrial cancer tissues. Knockdown of S100A2 inhibited cell viability, migration and invasion of endometrial cancer cells. Meanwhile, STING pathway was activated by the inhibited S100A2. STING inhibitor C-176 significantly reversed the effects of S100A2 knockdown on aggressive behaviours of endometrial cancer cells. Inhibition of S100A2 dramatically suppresses the tumour growth in vivo.
CONCLUSIONS: S100A2 functions as an oncogene in endometrial cancer. Targeting S100A2 may be a promising therapeutic method to treat endometrial carcinoma.
A sports electronic training system, and applications thereof, are disclosed. In an embodiment, the system comprises at least one monitor and a portable electronic processing device for receiving data from the at least one monitor and providing feedback to an individual based on the received data. The monitor can be a motion monitor that measures an individual's performance such as, for example, speed, pace and distance for a runner. Other monitors might include a heart rate monitor, a temperature monitor, an altimeter, et cetera. Feedback provided to a user typically includes, for example, training information such as whether the user is satisfying specific workout and/or training criteria. In an embodiment, the functionality of the sports electronic training system is enhanced by enabling the portable electronic processing device to interact with other devices and applications, for example, using the Internet.
<P>PROBLEM TO BE SOLVED: To provide a model animal having peritoneopatyhy under peritoneal dialysis.  <P>SOLUTION: A method for preparing a model animal having peritoneopatyhy under peritoneal dialysis includes a preparation step of preparing nonhuman animal having tissue disorder on the surface of peritoneum and administration step of administrating complement-activating factor in the peritoneum of the nonhuman animal. The preparation step may be a step including scraping of the surface of peritoneum. The administration step may be a step of administrating a liquid for peritoneal dialysis or osmotic pressure liquid in addition to the complement-activating factor into the peritoneum of the nonhuman animal and administration step may be practiced plural times. Further, the administration step may be a step of administrating a cell membrane component derived from fungus, especially zymosan as the complement-activating factor.  <P>COPYRIGHT: (C)2009,JPO&INPIT
We intend to explore potential mechanisms of Tripterygium wilfordii Hook.f (TwHF) induced kidney injury (KI) using the methods of network toxicology and molecular docking. We determined TwHF potential compounds with its targets and KI targets, obtained the TwHF induced KI targets after intersecting targets of TwHF and KI. Then we conducted protein-protein interaction (PPI) network, gene expression analysis, gene ontology (GO) function and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis to explore the mechanism of TwHF-induced KI. Finally we conducted molecular docking to verify the core toxic compounds and the targets. We obtained 12 TwHF toxic compounds and 62 TwHF-induced KI targets. PPI network, gene expression analysis and GO function enrichment analysis unveiled the key biological process and suggested the mechanism of TwHF-induced KI might be associated with inflammation, immune response, hypoxia as well as oxidative stress. KEGG pathway enrichment analysis indicated PI3K-Akt signaling pathway, HIF-1 signaling pathway and TNF signaling pathway were key signaling pathways of TwHF induced KI. Molecular docking showed that the binding energy of core targets and toxic compounds was all less than -6.5 kcal/mol that verified the screening ability of network pharmacology and provided evidence for modifying TwHF toxic compounds structure. Through the study, we unveiled the mechanism of TwHF induce KI that TwHF might activate PI3K-Akt signaling pathway as well as TNF signaling pathway to progress renal inflammation, mediate hypoxia via HIF-1 signaling pathway to accelerate inflammatory processes, and also provided a theoretical basis for modifying TwHF toxic compounds structure as well as supported the follow-up research.
Amlodipine group received 10 mg. A capsule was taken once daily in the morning for eight weeks. Capsules of amlodipine had identical presentation of that the intervention drug.
An approach is described with respect to functional age analysis. A method pertaining to such approach may include receiving sensor data collected on a plurality of individuals via a plurality of sensor devices. The method further may include constructing an age indices model by applying machine learning to the collected sensor data. The method further may include determining one or more functional age indices for a subject individual by applying the age indices model to profile data associated with the subject individual. In an embodiment, the method further may include transmitting the one or more functional age indices determined for the subject individual to a professional or a knowledge base, and receiving and processing one or more prescribed recommendations for the subject individual. According to such embodiment, the method further may include updating the age indices model based upon feedback received with respect to the one or more prescribed recommendations.
Methods are disclosed for removing retained mucus secretions from the lungs of a human subject. The method includes (1) generating an aerosol suspension of respirable solid, dry particulate amiloride, and (2) delivering by inhalation the aerosol suspension to the respiratory system of the subject. The solid particulate amiloride is comprised of particles of about 1 to 5 microns and is free of liquid amiloride particles. The aerosol suspension of respirable solid particulate amiloride is administered in an amount sufficient to achieve concentrations of amiloride on the airway surfaces of from about 10 -7  to 10 -3  Moles/liter. As a result of the treatment, the secretions are hydrated and more easily transported from the lung via mucociliary action. Methods are also disclosed for the treatment of cystic fibrosis in humans.
HF is a life-threatening condition in which the heart can no longer pump enough blood to the rest of the body. It is important for individuals with heart failure to closely monitor their symptoms, seek out medical attention when appropriate, and effectively self-manage their condition. However, people with HF are often frail, poor, and socially isolated. These factors may limit their ability to access clinic-based services and self-manage their condition. Research has shown that group health care visits with other HF patients and peer support for self-care behaviors are effective at improving heath care outcomes. This study will use an interactive voice response (IVR) system, which is a low-cost telephone system that allows calls to be made through a central 1-800 number, thereby eliminating the need to distribute home phone numbers or pay for long distance calls. Through the IVR system, participants will receive and provide peer support by sharing and discussing HF self-management techniques. The IVR system will also facilitate patient communication with care managers. This study will evaluate the effectiveness of the peer-to-peer IVR program in combination with group health care visits led by HF nurses at reducing hospitalization and death rates among HF patients. Participants will be drawn from a community health care system that primarily serves large numbers of racial minority and socioeconomically vulnerable people.

This study will enroll 288 moderate- to high-risk HF patients from St. Joseph Mercy Health System in Ypsilanti, Michigan. Participants will be paired up with another HF patient, based on gender and illness severity. Each pair will be randomly assigned to receive either usual care or usual care plus the nurse-led group visits and the IVR program. Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager. At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies. Study staff will monitor participants' use of the IVR system, including the dates, duration, and recipients of all phone calls. At Months 6 and 12, all participants will complete questionnaires and undergo a medical record review to assess hospitalization and death rates, quality of life, self-management behaviors, social support, satisfaction with HF care, and depression symptoms.